NTC 801
Alternative Names: BMS-914392; BMS-914392-01; NTC-801; NTC-801FLatest Information Update: 22 Apr 2021
At a glance
- Originator Nissan Chemical Industries
- Developer Nissan Chemical Industries; Teijin Pharma
- Class Antiarrhythmics
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atrial fibrillation; Atrial flutter
Most Recent Events
- 22 Apr 2021 Discontinued - Phase-I for Atrial fibrillation (In volunteers) in USA (PO)
- 22 Apr 2021 Discontinued - Phase-II for Atrial fibrillation in United Kingdom, Japan (PO)
- 22 Apr 2021 Discontinued - Phase-II for Atrial flutter in Japan (PO)